Sign in or Register   Sign in or Register
  |  

Rat Anti-LRRC32 Recombinant Antibody (CBYJL-2009) (CBMAB-L2108-YJ)

Provided herein is a Rat monoclonal antibody, which binds to Leucine Rich Repeat Containing 32 (LRRC32). The antibody can be used for immunoassay techniques, such as FC.
See all LRRC32 antibodies

Summary

Host Animal
Rat
Specificity
Human
Clone
CBYJL-2009
Antibody Isotype
IgG2a
Application
FC

Basic Information

Specificity
Human
Antibody Isotype
IgG2a
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Buffer
PBS, pH 7.4
Storage
Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
leucine rich repeat containing 32
Introduction
LRRC32 is a type I membrane protein which contains 20 leucine-rich repeats. Alterations in the chromosomal region 11q13-11q14 are involved in several pathologies.
Entrez Gene ID
2615
UniProt ID
Q14392
Alternative Names
GARP; D11S833E; leucine-rich repeat-containing protein 32; garpin; glycoprotein A repetitions predominant
Function
Key regulator of transforming growth factor beta (TGFB1, TGFB2 and TGFB3) that controls TGF-beta activation by maintaining it in a latent state during storage in extracellular space (PubMed:19750484, PubMed:19651619, PubMed:22278742).
Associates specifically via disulfide bonds with the Latency-associated peptide (LAP), which is the regulatory chain of TGF-beta, and regulates integrin-dependent activation of TGF-beta (PubMed:22278742).
Able to outcompete LTBP1 for binding to LAP regulatory chain of TGF-beta (PubMed:22278742).
Controls activation of TGF-beta-1 (TGFB1) on the surface of activated regulatory T-cells (Tregs) (PubMed:19750484, PubMed:19651619).
Required for epithelial fusion during palate development by regulating activation of TGF-beta-3 (TGFB3) (By similarity).
Biological Process
Negative regulation of activated T cell proliferationIEA:Ensembl
Negative regulation of cytokine productionIEA:Ensembl
Positive regulation of gene expressionIEA:Ensembl
Regulation of transforming growth factor beta activationManual Assertion Based On ExperimentIDA:UniProtKB
Regulation of transforming growth factor beta3 activationIEA:Ensembl
Secondary palate developmentISS:UniProtKB
Transforming growth factor beta receptor signaling pathwayManual Assertion Based On ExperimentIDA:UniProtKB
Cellular Location
Cell membrane
Cell surface
Involvement in disease
Cleft palate, proliferative retinopathy, and developmental delay (CPPRDD):
An autosomal recessive disorder characterized by mild to severe intellectual disability with delayed or absent speech, hypotonia, cleft palate, proliferative retinopathy, and combined sensorineural and conductive hearing loss. Brain imaging shows ventriculomegaly, widened subarachnoid spaces, partial agenesis of the corpus callosum, hypoplastic cerebellar vermis, and Dandy Walker malformation.
Topology
Extracellular: 20-627
Helical: 628-648
Cytoplasmic: 649-662

Li, Y. K., Wang, H. Y., Chen, Y., Shi, X. Q., Zhang, X. X., Li, K., ... & Sun, C. (2023). Single‑nucleotide polymorphism rs6592645 confers asthma risk through regulating LRRC32 expression. Experimental and Therapeutic Medicine, 26(3), 1-9.

Hexner-Erlichman, Z., Fichtman, B., Zehavi, Y., Khayat, M., Jabaly-Habib, H., Izhaki-Tavor, L. S., ... & Spiegel, R. (2022). A Novel Homozygous Missense Variant in the LRRC32 Gene Is Associated With a New Syndrome of Cleft Palate, Progressive Vitreoretinopathy, Growth Retardation, and Developmental Delay. Frontiers in Pediatrics, 10, 859034.

Lehmkuhl, P., Gentz, M., Garcia de Otezya, A. C., Grimbacher, B., Schulze-Koops, H., & Skapenko, A. (2021). Dysregulated immunity in PID patients with low GARP expression on Tregs due to mutations in LRRC32. Cellular & molecular immunology, 18(7), 1677-1691.

Chen, J., Chen, Q., Wu, C., & Jin, Y. (2020). Genetic variants of the C11orf30-LRRC32 region are associated with childhood asthma in the Chinese population. Allergologia et Immunopathologia, 48(4), 390-394.

Hennighausen, L., & Lee, H. K. (2020). The transcription factor STAT5 binds to distinct super-enhancer sites and controls Lrrc32 expression in a prominent autoimmune and allergic disease risk locus. bioRxiv, 2020-06.

Harel, T., Levy-Lahad, E., Daana, M., Mechoulam, H., Horowitz-Cederboim, S., Gur, M., ... & Elpeleg, O. (2019). Homozygous stop-gain variant in LRRC32, encoding a TGFβ receptor, associated with cleft palate, proliferative retinopathy, and developmental delay. European Journal of Human Genetics, 27(8), 1315-1319.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Rat Anti-LRRC32 Recombinant Antibody (CBYJL-2009)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare